Moomoo AIのまとめ
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
Avalo Therapeutics, Inc. has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity and securities offering related to a business combination transaction. The offering, which began on March 27, 2024, has already seen $130,601,986 sold out of a total offering amount of $199,976,986. The securities are being offered in connection with a merger involving Project Athens Merger Sub, Inc., AlmataBio, Inc., and Second Project Athens Merger Sub, LLC. Avalo Therapeutics has declined to disclose the issuer size and has claimed an exemption under Rule 506(b) of the Securities Act. The company, based in Rockville, Maryland, operates in the biotechnology industry and has listed several executive officers and directors in the filing. No sales commissions have been reported, but finder's fees of approximately $6,937,500 have been estimated. The proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters beyond their usual compensation.
アバロ・セラピューティクスは、SECに証券の免除公告を提出し、ビジネス統合の取引に関連する新しい株式および証券の公告を示しています。オファリングは、2024年3月27日に開始され、金額総額199,976,986ドルのうち、すでに130,601,986ドルが売れています。証券は、Project Athens Merger Sub, Inc.、AlmataBio, Inc.、およびSecond Project Athens Merger Sub, LLCが関わる合併に関連して提供されています。アバロ・セラピューティクスは、発行体の規模を開示せず、証券法のRule 506(b)に基づく免除を主張して...すべて展開
アバロ・セラピューティクスは、SECに証券の免除公告を提出し、ビジネス統合の取引に関連する新しい株式および証券の公告を示しています。オファリングは、2024年3月27日に開始され、金額総額199,976,986ドルのうち、すでに130,601,986ドルが売れています。証券は、Project Athens Merger Sub, Inc.、AlmataBio, Inc.、およびSecond Project Athens Merger Sub, LLCが関わる合併に関連して提供されています。アバロ・セラピューティクスは、発行体の規模を開示せず、証券法のRule 506(b)に基づく免除を主張しています。この会社は、メリーランド州ロックビルに拠点を置き、バイオテクノロジー業種で営業しており、いくつかの重役および取締役名を申請書に記載しています。売上手数料は報告されていませんが、約6,937,500ドルのファインダー料が推定されています。オファリングから得られた収益は、通常の報酬以外の、指名された重役、取締役、またはプロモーターへの支払いには使用されません。
役に立った
役に立たない